2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatment
2012
Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates
Butts SF, Ratcliffe S, Dokras A, Seifer DB. Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates. Fertility And Sterility 2012, 99: 382-388.e7. PMID: 23102859, PMCID: PMC3561490, DOI: 10.1016/j.fertnstert.2012.09.026.Peer-Reviewed Original ResearchConceptsLive birth rateAge 40 yearsART cyclesART coverageElevated FSHOvarian reserveTreatment outcomesReproductive technology treatment outcomesSpecific infertility diagnosisState insurance coverageReproductive technology cyclesDiminished ovarian reserveProportion of cyclesCross-sectional studyBirth rateReporting System databaseInsurance mandatesMix of patientsProvider factorsInfertility diagnosisMAIN OUTCOMEFSHSignificant associationTreatment prognosisAdditional studies
2006
Effects of HIV Infection and Its Treatment on Self-Reported Menstrual Abnormalities in Women
Massad LS, Evans CT, Minkoff H, Watts DH, Greenblatt RM, Levine AM, Anastos K, Young M, Seifer DB, Golub E, Cohen M. Effects of HIV Infection and Its Treatment on Self-Reported Menstrual Abnormalities in Women. Journal Of Women's Health 2006, 15: 591-598. PMID: 16796486, DOI: 10.1089/jwh.2006.15.591.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountComorbidityConfidence IntervalsFemaleHIV InfectionsHIV SeronegativityHIV SeropositivityHumansIncidenceMenstruation DisturbancesMulticenter Studies as TopicOdds RatioPrevalenceProspective StudiesRisk FactorsSurveys and QuestionnairesWomen's HealthConceptsHigher CD4 countsHIV-seropositive womenMenstrual abnormalitiesCD4 countHIV serostatusActive anti-retroviral therapy (HAART) useAnti-retroviral therapy useMulticenter prospective cohort studyCox proportional hazards modelProspective cohort studyHIV natural historyProportional hazards modelSeronegative womenHAART useCohort studyHIV infectionTherapy usePrevalent abnormalityMenstrual changesMenstrual problemsMost abnormalitiesNatural historyAbnormalitiesLogistic regressionWomen